SIP
DFTX

Stoneridge Investment Partners’s Definium Therapeutics DFTX Stock Holding History

Stoneridge Investment Partners’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,563
Closed -$136K – 151
2025
Q3 		$136K Buy
11,563
+804
+7% +$7.5K 0.09% 104
2025
Q2 		$70K Hold
10,759
– – 0.05% 116
2025
Q1 		$63K Hold
10,759
– – 0.05% 104
2024
Q4 		$75K Sell
10,759
-5,603
-34% -$38.5K 0.03% 126
2024
Q3 		$93K Buy
+16,362
New +$114K 0.03% 104

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Stoneridge Investment Partners's DFTX Position: Q4 2025 in Review

Stoneridge Investment Partners sold out of Definium Therapeutics (DFTX) in Q4 2025, closing a stake of 11,563 shares — an estimated $136K sold.

Stoneridge Investment Partners first reported a position in DFTX in Q3 2024 and held it in 5 quarters. The position peaked at $136K in Q3 2025. 208 funds tracked by Wall St. Rank hold DFTX as of Q4 2025.

  • Stoneridge Investment Partners reported no remaining Definium Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Stoneridge Investment Partners sold 11,563 Definium Therapeutics shares in Q4 2025, an estimated $136K.
  • Stoneridge Investment Partners first reported a position in Definium Therapeutics in Q3 2024 and held it in 5 quarters.
  • Stoneridge Investment Partners's Definium Therapeutics position peaked at $136K in Q3 2025.
  • 208 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2025.

Based on Stoneridge Investment Partners's 13F filing for Q4 2025, filed 5 Feb 2026.